Premium
Characterization of Circulating Tumor DNA for Genetic Assessment of solid Tumors
Author(s) -
Dorner AJ,
Badola S,
Niu H
Publication year - 2015
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.130
Subject(s) - circulating tumor dna , cancer , medicine , cancer therapy , liquid biopsy , solid tumor , precision medicine , cancer research , pathology , oncology
Personalized cancer therapy requires characterization of the current status of an individual's cancer, necessitating invasive tumor tissue biopsies at diagnosis, during treatment and at progression. Serial acquisition of solid tumor biopsies during treatment to characterize mutations related to acquired resistance may not be medically feasible. Circulating tumor DNA (ctDNA) in plasma offers a possible noninvasive “real time” tool for tumor characterization, providing accessible genetic biomarkers for cancer diagnosis, prognosis, and response to therapy.